Business Standard

AstraZeneca Covid drug neutralises Omicron sub-variants in lab study

Evusheld was tested against the BA.1, BA.1.1, and BA.2 sub-variants of Omicron and it was also shown in the study to limit inflammation in the lungs - a critical symptom in severe Covid-19 infections

Illustration: Reuters
Premium

Illustration: Reuters

Reuters
AstraZeneca said on Monday its antibody-based cocktail to prevent and treat COVID-19 retained neutralising activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study.

This is the first data looking at the impact of AstraZeneca's Evusheld treatment on "cousins" of the Omicron variant following a recent global spike in cases. The Anglo-Swedish drugmaker said in December that another lab study found that Evusheld retained neutralising activity against Omicron.

Data from the latest study by Washington University in the United States showed the therapy reduced the amount of virus detected in samples - viral load - of

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 21 2022 | 2:29 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com